UPDATE.SPECIAL

Pharma Days 2017May 16 – 17, 2017

Dresden (Germany) and Boleslawiec (Poland)

with photo impressions

WELCOME

CONTENT

Welcome 2

Summary of presentations 3

Plant portrait Boleslawiec 8

Gerresheimer Pharma Days 2017

JUNE 2017

UPDATESPECIAL

2 | JUNE 2017

aging plant and our Plastic Packaging plant in Boleslawiec, Poland. Our site in Poland is the only Gerresheimer location to produce both glass and plastic products. There has been a lot of investment into the Boleslawiec location in recent years, specifically in terms of the production and clean room technolo-gy that is used for vial production. During this portion of the event, customers were given the opportunity to see this technology first-hand. After an introduction from the plant managers Marek Miszczak and Janusz Filipiuk, the customers were taken on a detailed tour of the plants, during which, Gerresheimer experts explained the steps involved in the production of tubular glass as well as the ophthalmic packaging production process at six different stations.

Summaries of the presentations and work-shops, as well as numerous photos that pro-vide an overall impression of the two-day event, can be found on the following pages.

The first day included a wide variety of pres-entations and workshops from our Gerres-heimer team. After an introduction from con-ference chairman, Jens Heymann, the Gerres-heimer CEO, Uwe Röhrhoff, and Member of the Management Board, Andreas Schütte, provided our customers with insights into the Gerresheimer world: Uwe Röhrhoff gave an overview of our recent strategic adjustments, while Andreas Schütte focused on trends in medical systems and plastic packaging. The external keynote speaker, Franz Magerl, a well-renowned professor from East-Bavarian Technical University, shared some insights into the development and delivery process for primary packaging made of glass. The pres-entations were followed by a variety of work-shop sessions on the latest news and devel-opments, which focused specifically on quality, continuous innovation, and our technological leadership in the pharmaceutical packaging and medical devices industry.

On the second day of the event, the guests were shown around our Primary Glass Pack-

This was the eighth time we held our most impor-tant customer event, Gerresheimer Pharma Days, which was execut-ed successfully. About 60 participants from all over Europe met in Dresden,

Germany during the middle of May to listen to presentations from our team, take part in a variety of workshops, and network with others.

One of the highlights of the two-day event was a tour of the Boleslawiec, Poland pro-duction plants, which is our only site to pro-duce both plastic and glass packaging. Our guests gained a lot of useful information, took a positive lasting impression back home with them, and gave us some very positive feedback.

This response has motivated us to continue the Pharma Days tradition and organize an-other event in 2018. This issue of Update provides a summary of Pharma Days 2017, as well as a number of insights into how the event played out. We are glad the experience was met with such enthusiasm from the at-tendees, and we look forward to future Phar-ma Days!

Jens KürtenGroup Senior Director Communication & Marketingj.kuerten@gerresheimer.com

On May 16 and 17, 2017, approximately 60 international pharmaceutical industry customers convened at the Gerresheimer event in Dresden, Germany to visit the nearby production area and learn more about the pharma industry through a program packed full of events.

UPDATE.SPECIAL

3 | JUNE 2017

Gerresheimer’s production lines produced 15.5 billion products in 2016, making it the market leader for prima-ry packaging and medical devices with its 40 sites across Europe, the US, South America, and Asia. We have more than 1,500 customers, including the top ten biggest phar-ma companies. The products we produce in 14 countries around the world are in demand in 97 countries spread across five continents. We rigorously pursue our goals in order to improve even further. These goals include our acquisition of “Centor”, which has now been fully inte-grated into the company; the expansion of our Peachtree City plant in the US; our break-off from our Life Sciences Research department for strategic reasons; and the refur-bishing of our plant in Tettau to produce packaging for the cosmetics sector.

We were able to expand the clean room technology at our production sites in Poland, Brazil, and India, as well as successfully driving our global vial machine strategy forward. The secret to our success includes knowing what our customers want and need from a product and devel-oping specialized solutions to meet those requirements. Our customers include major pharma firms as well as small and medium-sized companies producing specialized prod-ucts or generics. They all rely on the fact that we know and understand their specific requirements.

SUMMary Of PrESENTaTiONS

Global Excellence for Pharma and HealthcareUwE RöhRhoff Gerresheimer AG, Chief Executive Officer

Our Competence for Next Generation Medical SystemsAnDREAs schüTTE Gerresheimer AGMember of the Management Board with responsibility for Plastics & Devices

Conference Chairman:

JEns hEymAnnGerresheimer

For us, this means consistently delivering the same quality, understanding the processes surrounding the launch of a preparation on the market, and, what is more, guaranteeing the greatest possible flexibility. The zero-de-fect strategy, combined with ensuring a reliable supply chain, is just one key aspect. Production sites around the world with an integrated global support team in conjunc-tion with a wide range of products, and efforts to achieve technical and regulatory perfection complete the picture. On average, we invest 8% of our revenue to achieve these aims, focusing on optimizing production processes, stand-ardizing and improving our production machinery around the world, and increasing our use of clean room technol-ogy.

But the list of future investment opportunities also includes sustainability and environmental protection as well as investing in emerging economic regions and de-veloping markets. The best example when it comes to optimization is our global vial machine strategy: We have created a common unified production standard for the manufacture of vials at a number of our plants around the world. This means that our production sites spread across the globe use virtually all the same technology and, in terms of quality control, the same monitoring and in-spection systems are employed worldwide, all subject to the same regulations.

With growth rates of around 10%, injectables have a growing share of the fiercely competitive global pharma market. The trend here is towards bioengineered drugs and a customized form of medicine that moves beyond the classic blockbuster drugs. Increasingly complex med-ical devices as well as portable injection systems and in-telligent drug administration systems are needed to ensure compliance and patient monitoring when it comes to these new forms of treatment. The customer landscape is also changing due to mergers and new alliances between pharma companies and IT/internet firms. We are tackling these challenges with a high degree of flexibility when working with our customers, with our spectrum of exper-tise ranging from sales and order completion through to

product development. As a development partner, we offer support in all the key stages of the product life cycle, from product design, industrialization, and licensing through to finishing and packaging. Our comprehensive range of products also allows us to significantly reduce the time to market and thus hone our customers’ com-petitive edge. Design development and IP processes run in parallel as part of a robust style of project management that is closely coordinated with the customer. This is un-derpinned by an international focus geared toward value chains and logistics processes distributed across the world as well as small-batch production that allows us to produce and fill prototypes, clinical samples, or initial product batches at every stage of the development process.

UPDATE.SPECIAL

4 | JUNE 2017

Virtual product development process of drug delivery devices and primary packaging made of glassPRof. DR. fRAnz mAgERl East-Bavarian Technical University of Applied Sciences

Excellence in vial production – rollout of the Gerresheimer vial machine strategyslAwomiR miREk Gerresheimer Primary Packaging Glass

Bringing together all available models and data creates a perfect digital “twin” that lets product and process de-velopment and all the related challenges be simulated reliably in a virtual environment, something that begins right at the glassmaking stage. The simulation allows critical parameters relating to the quality of the glass produced, the energy consumed, and the emissions gen-erated to be determined, thus guaranteeing stable, high-quality, and environmentally friendly production. When processing container or molded glass, the next step is to produce glass gobs and transport them to the mold-ing station, where corresponding simulations can calculate the optimum temperature profiles for the gobs as well as their ideal discharge and transportation speed. In the downstream molding processes, the simulation techniques make it possible for high temperature differences between

the molten glass and the tools as well as extreme defor-mation in the glass during the molding process to be handled reliably. Gerresheimer’s predictive engineering analytics is a similarly powerful tool that helps with the manufacture and processing of tubular glass. It provides a virtual space for simulating the complex interplay be-tween glass infeed and drawing speeds, temperature, and pressure in order to guarantee a robust, top-quality pro-duction process. As with container glass, simulation tech-niques then facilitate optimum control over heating, cutting, forming, and surface finishing processes.

Virtualizing the entire development and process chain generates extensive insights for identifying, evaluating, and monitoring the crucial parameters that influence process stability and product functionality.

Pharma companies are facing increasingly stringent re-quirements. To navigate these demands even better and more quickly, Gerresheimer has launched its very own global vial strategy. With a high level of capital investment, the aim is not just to comply with the current industry standard for tubular glass processing, but to exceed it. The key factor here is the vertical production plant with an SD36 forming machine at its core. The new production concept allows us to standardize quality control, inspec-tions, and packaging technology. Its rollout in the US is already complete, while four machines are up and running at the Bolesławiec site in Poland with more to follow. Work began on installing the first machine in April 2016 and the final machine is currently due to be converted this November. The benefits of machine conversion are obvious: An improved forming process renders the glass extremely stable.

All vials are checked more quickly and efficiently for tiny visual defects using a Gx® G3 camera. The process is similar when it comes to verifying other quality parame-ters: All vials are thoroughly checked using Gx® RHOC, whereby a real-time control identifies defects directly after they appear and helps significantly reduce the total cost of ownership, since defective vials can be removed from the production process at an early stage. This so-called zero-defect strategy builds a strong case for phar-ma companies around the world, as all Gx® RHOC and Gx® G3 data are transmitted to the InfinityQS during production. The powerful software tool analyzes the qual-ity of the charge while production is still ongoing and allows the head of manufacturing to intervene immedi-ately or stop the process to eliminate the causes of defects.

TOPiC 1 OUr COMPETENCE aND TECHNOLOGiCaL LEaDErSHiP

UPDATE.SPECIAL

5 | JUNE 2017

Operational excellence in ophthalmic primary packagingmAREk miszczAk Gerresheimer Plastic Packaging

The Center of Excellence for ophthalmic primary packag-ing in Bolesławiec offers 65 years of experience, cut-ting-edge production plants, highly qualified and moti-vated staff, validated processes, modern logistics, and seamless quality management. Our primary packaging made from plastic ranges from bottles and closure systems for packaging solids and liquids, spray and dropper bottles for opthalmic applications, through to MultiShell® vials for the most sophisticated medicines. Ever since our first-generation ophthalmic dropper bottles in 1970, we have continuously developed our production technology, the quality of our products, and their technical medical and ergonomic capabilities. Working closely with the

other divisions at Gerresheimer, we develop complete solutions to the challenges facing the pharma market: from the trend toward bioengineered drugs and the in-creasingly stringent regulatory requirements through to the ever greater emphasis on self-medication. When it comes to product development, we follow the “quality by design” principle, a comprehensive concept where we guarantee consistent product quality in line with specifi-cations by identifying and controlling all of the key process parameters. What is more, we always develop products with patients as the end users in mind to help them get the easiest and safest use out of our packaging.

Manufacturing devices using a fully automated material flow PETER fElbER Gerresheimer Medical Systems

Gerresheimer applies a fully integrated ISO 8 clean room concept to the multilevel production process that it uses to make its pharmaceutical devices. What makes this concept unique is how all the process steps are arranged one after the other with no barriers between them and no infiltration or discharge tasks.

With the production processes that add value, such as injection molding and assembly, already having been largely automated over the past few years, the manufac-turing planning team with global responsibility have now taken up the challenge of automating all elements of the material flow in the factory as well. Starting with the raw material, they successfully automated the manual handling of granulate using rail-mounted vacuum grippers and self-emptying octabins.

The next stage in the process will see material dried precisely, including full traceability for parameters and batch data, for which Gerresheimer has chosen to devel-

op its own easy-to-operate controller with touch panel. Sophisticated coupling stations then convey the prepared material to the correct injection molding machines where the granulate is turned into the plastic components re-quired for the devices. All interfaces on these machines have been standardized to suit all manufacturers and all of Gerresheimer Medical Systems’ global production sites. The injection-molded parts are moved onto special turn-tables via handling devices and conveyor belts. At the company’s Pfreimd site, the onward transport of contain-ers will also be fully automated before the end of the year using so-called automated guided vehicles (AGVs). Every container is given a visual quality check shortly after pro-duction. The new self-driving aids also allow the tubs to be stacked into palletized containers and placed into the integrated ISO 8 high-bay warehouse fully automatically. The next stage of the upgrade will see the automation of the logistics system to include the assembly lines.

Zero Defect approachDR. VolkER REkowski Gerresheimer Primary Packaging Glass and Gerresheimer Quality Council

It is becoming increasingly important nowadays to take a holistic view of quality rather than simply limiting it to your production processes. This is because it is not only a defective product that reduces customer satisfaction – supply bottlenecks and poor service management also have the same effect. If a company and all its departments embrace and implement a zero-defect approach, this can make for much happier and more loyal customers. How-ever, the focus needs to be on all processes.

One effective way to implement such a strategy is the “product-by-process” approach, whereby each individu-al production step is considered in advance to identify potential sources of error. Production does not get under way until the process as a whole has been evaluated in detail. This guarantees that the goods being manufactured share the same quality at all times and comply with the relevant specifications. The best example is the commis-

sioning of the SD36 production line: Its technical equip-ment, which has been standardized, was subjected to a risk assessment before being rigorously verified, installed across the world, and trialled as part of the process. De-viations from the set criteria during technical installation were only made in exceptional cases.Worldwide, “real-time process control” ensures rapid data capture and enables the process to be adjusted immediately – a process that ultimately results in identical high-quality products. It was also possible to bring about technological improvements to design aspects following an in-depth inspection of all systems installed anywhere in the world and making use of RCFA (Root Cause Failure Analysis), thus allowing the process design to be enhanced even further. Out of this has emerged a global list of errors and faults, which makes troubleshooting more efficient at every production site worldwide.

TOPiC 2 ExCELLENT qUaLiTy

UPDATE.SPECIAL

6 | JUNE 2017

a risk-based approach for successful device productionmARkUs REil Gerresheimer Medical Systems

Gx Solutions – enhanced range of biotech and specialty pharma products and solutions mAnfRED bAUmAnn Gerresheimer Medical Systems

TOPiC 3 CONTiNUOUS iNNOVaTiON

With Gx Solutions, Gerresheimer is establishing a new overarching unit that can focus even more closely and more efficiently on the increasing demands of specific groups of customers. In particular, it will be addressing companies that manufacture biotech drugs and so-called specialty pharma. The market for biotech drugs and spe-cialty pharma is growing, with studies expecting it to be worth up to 525 billion U.S. dollars for specialized prepa-rations by 2021. The same can be seen in the global development pipeline of drugs: More than 300 medicines, which are around 30% of all preparations currently being developed, are biopharmaceuticals undergoing phase-III clinical trials. While vaccines and heparin once largely dominated the syringe market, bioengineered drugs have been gaining importance more recently.

Computer modelling of the glass moulding processPhiliPP AmRhEin Gerresheimer Primary Packaging Glass

When it comes to developing pharmaceutical primary packaging, our customers expect the packaging to protect both the drugs and their users, to be produced sustain-ably, and to be launched on the market as quickly as possible. The guiding forces helping us achieve these goals are product design, tool design, and our expertise in forming processes. The functional requirements of the product and the mechanical loads are crucial factors when fleshing out our product design, as are the configuration of the process window and the tool structure when it comes to tool design. Specific requirements for the prod-uct can include the type of closure system, tamper-evident seals, decorative elements and labels, and its behavior on

Devices face a wealth of quality requirements ranging from regulatory specifications and customer-specific prod-uct characteristics through to demands driven by key performance indicators. What is referred to in this field as the voice of the customer (VoC) must be translated into specific figures (CTQs) for the development process. This strategy is underpinned by rigorous risk management that generates interconnected risk ratings (FMEAs) for every phase of the product life cycle. Each of these risks can range from a negligible threat to a catastrophic haz-ard and is given a corresponding rating out of five or scored according to a fixed scale of severity ratings. This score is relayed along every stage of the product devel-

the filling line. A simulation using finite element analysis (FEA) can be used to determine the mechanical loads and thus also the wall thickness required of a product concept adapted to these requirements. This can then be used as a basis for producing a digital design of the process win-dow, as a tool for the product, and to simulate the be-havior of the glass during forming using computational fluid dynamics (CFD). The simulation technology used here is so sophisticated that the predicted and actual product characteristics are almost identical, avoiding time-consuming correction loops during toolmaking and enabling a much faster time to market.

In the future, therefore, both small and medium-sized pharma companies and major corporations will have to rely more heavily on their ability to develop and produce customized medical devices and special primary packag-ing solutions for their different active ingredients. Ger-resheimer is tackling these requirements already with its new unit, which hopes to promote new developments on the device and primary packaging market and get them ready for launch even faster. Examples of similar Gerres-heimer developments include its metal-free prefillable syringe systems, sterile prefillable vials, new grades of glass such as Elite and Valor, and much more. The new Gx Solutions unit will be based in the Medical Systems business unit for organizational purposes, where it will gain much of the support it needs, including the expertise of the Gerresheimer Technical Competence Center (TCC) in Wackersdorf, although it will also receive support from other units in the Gerresheimer Group.

opment cycle, serving as a basis for the product validation strategy and that of the associated facilities and process-es. A minimum requirement is a strategy that reduces the risk to patients as much as possible, while also meeting additional financial, marketing, and operator safety re-quirements. The identified risk helps determine the degree of validation required. When progressing from the vali-dation to the production phase (and thus from CRQ to AQL values), manufacturers also recognize that long-term data is worth less than short-term data as per the litera-ture. They should therefore aim for values above the re-quired level of production quality during validation.

UPDATE.SPECIAL

7 | JUNE 2017

Gx® rTf vials – a market standard for greater flexibilitymAximiliAn Vogl Gerresheimer Medical Systems

innovations in tubular glass to meet future demands of the pharma industryRogER kURinsky Gerresheimer Primary Packaging Glass

Markets and regulatory authorities are imposing increas-ingly stringent quality requirements on the pharma indus-try. Our aim is to make problems with primary packaging a thing of the past, leaving our customers with more time to devote to their core business. One option in this regard is to use high quality vials called Gx® ELITE. These vials are essentially flaw free and dimensionally perfect, en-suring superior filling line efficencies. Gx® ELITE vials are resistant to more than twice the mechanical load of oth-er standard vials. Although they now boast new quality features, they do not need to be re-certified because they are produced from type I glass. They are visually flawless, comply with particularly narrow dimension tolerances,

Gerresheimer has expanded its Gx® RTF portfolio with the addition of Gx® RTF vials, whose packaging is produced using Ompi EZ-fill technology, where prefillable vials are washed with WFI, sterilized with ethylene oxide, and packaged in either trays or nests and tubs. Glass-to-glass contact is consistently avoided during processing and packaging in order to prevent cosmetic errors from creep-ing in. Pharma customers can then unpack and fill the vials without the need for any further preparation. This means no additional costs are incurred for sterilization and washing, less clean room space is required, and the outlay involved in validating packaging preparation pro-cesses is eliminated. Gx® RTF vials ensure a high degree of flexibility, minimal total cost of ownership, and a short-

In the biopharmaceuticals sector the trend is moving away from familiar blockbusters toward a customized form of medicine that allows a special active biopharmaceutical ingredient to be administered in a form and dosage tailored to the patients’ needs. The major challenge facing the development of primary packaging is the fact that no two biopharmaceuticals are the same, either in terms of their composition or their annual demand. This is clear, for example, when you compare the the bispecific antibody blinatumomab (trade name Blincyto®) with the monoclo-nal antibody evolocumab (trade name Repatha®), or even insulin. While only 7 grams of Blincyto® are required per year, this is three metric tons for Repatha® and an esti-mated 1,000 metric tons plus for insulin.

With its RTF® packaging, Gerresheimer offers solutions that are ideally suited to active pharmaceutical ingredients with their specific characteristics, while guaranteeing optimal use for the customer. Yet what specific require-ments must a syringe system meet with biopharmaceuti-cals? In addition to reducing tungsten, silicone oil, resid-

and are especially unlikely to delaminate thanks to the use of the Gx® THOR temperature control during produc-tion. Cell packaging ensures that the products maintain their production quality en route to the customer. In ad-dition, Gerresheimer can now also offer innovative Valor vials and cartridges thanks to its partnership with glass expert Corning. Valor is an aluminosilicate glass that is particularly suited to demanding medical technology ap-plications. The Valor ion exchange process increases the material’s hardness tenfold, while the surface of the end product is also given a special Valor coating to optimize finishing in the filling plant and safeguard the quality of the product for the long term.

Latest developments in prefillable syringe systems tackling new challenges and patient needsclAUDiA PETERsEn Gerresheimer Medical Systems

er time to market because they can be used at every development stage, from clinical testing through to in-dustrial-scale production. The standardized Ompi EZ-fill technology also allows all manner of different RTF pack-aging types to be filled on a single production line, from ISO and customer-specific vials through to syringes. This not only helps reduce risks using dual sourcing but also cuts costs, spatial requirements, and the use of resources during filling across the board. This means the tradition-al filling method for bulk products now only offers cost benefits during the large-scale production of a single type of packaging. By contrast, the new RTF packaging tech-nology is the more economical solution for small and medium-sized batches with different types of packaging.

ual adhesive, and particles that could interact with the sensitive formulation, issues such as dosage accuracy are also becoming important. This is the only way to avoid additional costs from overfilling and to reduce the total cost of ownership. The requirements for glass packaging with respect to using syringes in autoinjectors should also be agreed in advance in order to guarantee an optimum shape and functionality. The specific syringe measurements influence key device functions such as the needle pene-tration depth and tightness.

Metal-free syringes where the tungsten pin has been replaced by a ceramic one are another development that meets the current demands of the biotech segment. Our partnership with Japanese company Taisei Kako sparked a desire to build a production facility for prefillable COP syringes in Europe, too. With our partner’s help, we now have the widest-ranging portfolio in the industry and are set to launch the 1-ml-long SIN syringe with Aptar Stelmi RNS and TERNS in 2018 and the 1-ml-long TELC in the following year.

UPDATE.SPECIAL

8 | JUNE 2017

A small state-owned glassworks for pharma-ceutical vials and ampoules, established in this small Polish town in July 1952, was the foundation for today’s Gerresheimer Boles-lawiec.

The original vial and ampoule production op-erations were successively expanded to include further pharmaceutical packaging products. By the mid-1980s the company had become a strong player in the Polish market, offering its customers a comprehensive portfolio of pharmaceutical packaging products in glass, plastic and aluminum. In 1995 it was convert-ed into a public limited company trading un-der the name of Bolesławiecka Fabryka Ma-teriałow Medycznych, though it was also known as “Polfa”.

gerresheimer boleslawiec

65 years of expertise in manufacturing plastic and glassBoleslawiec is the only plant in the entire Gerresheimer Group to manufacture pharmaceutical packaging products from both glass and plastic. It is located in southern Poland and enjoys a longstanding tradition as pharmaceutical packaging manufacturer.

acquisition by Gerresheimer

Two years later, Gerresheimer acquired a ma-jority shareholding in Polfa - the first step of its expansion strategy into Poland and other eastern European markets. By 2003, Gerres-heimer had also purchased the remaining shares in the company. After the take over, all activities that had nothing to do with the core business of pharmaceutical packaging products were spun off.

Highest quality standards

The breakthrough came for Gerresheimer Boleslawiec S.A. in 2008. It has continuously developed new markets and improved its production quality, which is reflected in cus-tomer audits, customer surveys and the reg-

ular quality audits. The plant is certified as compliant with the ISO 9001 quality standard, ISO 14001 environmental standard, the ISO 15378 primary packaging product standard and the ISO 14664 cleanroom standard. The cleanrooms are all ISO class 7. The primary packaging produced in Boleslawiec is regis-tered with the FDA as DMF type III.

UPDATE.SPECIAL

9 | JUNE 2017

gerresheimer boleslawiec

PrODUCT POrTfOLiO

Tubular Glass Products

Ampoules with OPC, break ring or code ring, printed and non-printed, clear and amber injection vials, tablet jars, screw-top bottles, snap ring vials

Plastic Products

Bottles, droppers, caps and closures, spray and pump systems for ophthalmic and nasal applications, contact lens care bottles

MultiShell® plastic vials

Innovative vials which unite the best properties of plastic and glass in a new and high quality packaging for paren-teralia

SPECiaLTiES

FDA registered, DMF type III Chemical and microbiological

laboratory Radiation or ETO sterilisation

on request Clean-room technology ISO 9001 ISO 14001 ISO 15378

Broad range of glass and plastic products

Around 530 people currently work at the Boleslawiec plant. The ‘top sellers‘ manufac-tured there for the Tubular Glass Business Unit are vials and ampoules. In fact, the plant turns out several hundred million of them every year, plus several hundred million cartridges and samplers. The most important product for the Plastic Packaging Business Unit is the plastic vial that is used for liquid medications such as eye drops, and production output of these vials has increased more than ten-fold since 2000. Other plastic products which are

manufactured in Boleslawiec include droppers, spray and pump systems, contact lens care bottles, and closures and there has also been three-digit growth in these product segments in recent years.

Synergetic effects between tubular glass and plastic production operations provide a com-petitive advantage that pharmaceutics cus-tomers around the world appreciate. For example, the HR, IT and accounting depart-ments deal with both glass and plastics cus-tomers, who can place their orders for plastic and glass packaging on a one-stop basis.

Gerresheimer Boleslawiec today

This year, Gerresheimer Boleslawiec celebrates its 65th anniversary. The former state-owned company which predominantly manufactured its products for the Polish market has evolved into an international, export-oriented produc-tion facility in the Gerresheimer Group. The plant’s successful track record, committed employees and continuous improvement ef-forts provide an excellent basis for its future success.

Glass vials are the most frequently used packaging for injectables in the world. Ger-resheimer manufactures them in the Amer-icas, Asia and Europe with filling volumes of between 1 and 50 ml. Gerresheimer has set up an investment program spanning several years to install state-of-the-art con-verting machines for vial manufacturing from tubular glass at all its vial plants. The latest-generation machines and the high standards that apply on a global basis will

allow Gerresheimer to meet even more stringent product quality requirements in the future.

The new machines have now been installed at all the American vial plants. In Bolesławiec, where one of Gerresheimer’s two European Excellence Centers for vial production in Europe is located, the first four machines were installed and put into operation. More new machines will follow end of 2017.

Global vial machine strategy now implemented in Boleslawiec

www.gerresheimer.com

High-Quality Gx® Primary Packaging and Medical Devices

High performance design | High barrier properties | Superior resistance